Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | SOST | Q9BQB4 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.75 |
| ▸ | APP | P05067 | 1/20 | 0.75 |
| ▸ | XDH | P47989 | 2/20 | 0.67 |
| ▸ | IDO1 | P14902 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taxifolin SCHEMBL29390633 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL30300501 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL30631315 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL29361519 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL13241264 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL296323 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL29368246 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Epitaxifolin SCHEMBL31575455 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL1707803 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL29367955 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580594-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG (DE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024046834-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | ANALYTICON DISCOVERY GMBH (DE) | 2024-03-07 | — | — | WO | disclosed |
| EP-4331564-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | Analyticon Discovery GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| CN-109316438-A | A kind of preparation method of the solid precursor liposome with acne-removing | 珀莱雅化妆品股份有限公司 | 2019-02-12 | — | — | CN | disclosed |
| CN-104910121-A | Taxifolin preparation method | NANJING ZELANG BIOTECHNOLOGY CO LTD | 2015-09-16 | — | — | CN | disclosed |
| US-8536363-B2 | Compounds and methods for delivery of prostacyclin analogs | UNITED THERAPEUTICS CORPORATION (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120295980-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION | 2012-11-22 | — | — | US | disclosed |
| WO-2010134580-A1 | METHOD FOR PRODUCING AROMATIC FLUORINE COMPOUND AND NOVEL COMPOUND | 静岡県公立大学法人 (JP) | 2010-11-25 | — | — | WO | disclosed |
| US-7524836-B2 | Nitrooxyderivative steroidal compounds | NICOX S.A. (FR) | 2009-04-28 | — | — | US | disclosed |
| US-20070142342-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-06-21 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| EP-1003528-B1 | METHOD OF ENHANCING BIOAVAILABILITY OF FEXOFENADINE AND ITS DERIVATIVES | AVENTIS PHARMA INC (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6451815-B1 | Method of enhancing bioavailability of fexofenadine and its derivatives | AVENTIS PHARMACEUTICALS INC. | 2002-09-17 | — | — | US | disclosed |
| EP-1003528-A1 | METHOD OF ENHANCING BIOAVAILABILITY OF FEXOFENADINE AND ITS DERIVATIVES | Aventis Pharmaceuticals Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999008690-A1 | METHOD OF ENHANCING BIOAVAILABILITY OF FEXOFENADINE AND ITS DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142342-A1 | Pharmaceutical compounds | CYP11B2, CYP11B1, CYP2S1 | CYP3A4 33/4885ALOX15 325/4885MAPT 3031/4885 |
| US-20120295980-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIS, PGF, PTGIR | CYP3A4 1064/4885ALOX15 92/4885MAPT 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.